InsiderTrades.com logo
DeFi Coin on Verge of Breakout!
From Crypto 101 Media   |   Ad
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Claim your FREE book now before it's too late!

CDT Insider Trading

Insider Ownership Percentage: 34.74%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,447,018.19

Conduit Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Conduit Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Conduit Pharmaceuticals Share Price & Price History

Current Price: $0.10
Price Change: ▲ Price Increase of +0.0081 (8.90%)
As of 11/26/2024 03:39 PM ET

This chart shows the closing price history over time for CDT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
DeFi Coin on Verge of Breakout!
From Crypto 101 Media   |   Ad
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Claim your FREE book now before it's too late!

Conduit Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2024Ltd NirlandMajor ShareholderSell939,009$0.10$93,900.906,092,000View SEC Filing Icon  
10/4/2024Ltd NirlandMajor ShareholderSell1,368,991$0.10$136,899.107,031,009View SEC Filing Icon  
10/2/2024Ltd NirlandMajor ShareholderSell333,177$0.10$33,317.709,900,000View SEC Filing Icon  
9/30/2024Ltd NirlandMajor ShareholderSell1,016,823$0.12$122,018.7611,483,177View SEC Filing Icon  
7/17/2024Andrew ReganDirectorSell1,514,100$0.26$393,666.00177,627View SEC Filing Icon  
7/15/2024Andrew ReganDirectorSell1,005,200$0.25$251,300.0011,936,119View SEC Filing Icon  
7/12/2024Andrew ReganDirectorSell1,389,820$0.25$347,455.0012,941,319View SEC Filing Icon  
7/10/2024Andrew ReganDirectorSell150,000$0.33$49,500.0015,214,091View SEC Filing Icon  
7/8/2024Andrew ReganDirectorSell35,923$0.51$18,320.7315,441,772View SEC Filing Icon  
7/3/2024Andrew ReganDirectorSell1,000$0.64$640.0015,477,695View SEC Filing Icon  
See Full Table
DeFi Coin on Verge of Breakout!
From Crypto 101 Media   |   Ad
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Claim your FREE book now before it's too late!

SEC Filings (Institutional Ownership Changes) for Conduit Pharmaceuticals (NASDAQ:CDT)

3.29% of Conduit Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Conduit Pharmaceuticals logo
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Read More on Conduit Pharmaceuticals

Today's Range

Now: $0.10
Low: $0.09
High: $0.10

50 Day Range

MA: $0.11
Low: $0.09
High: $0.14

52 Week Range

Now: $0.10
Low: $0.08
High: $7.83

Volume

9,496,471 shs

Average Volume

9,564,260 shs

Market Capitalization

$10.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Who are the company insiders with the largest holdings of Conduit Pharmaceuticals?

Conduit Pharmaceuticals' top insider investors include:
  1. Andrew Regan (Director)
  2. Ltd Nirland (Major Shareholder)
Learn More about top insider investors at Conduit Pharmaceuticals.
DeFi Coin on Verge of Breakout!
From Crypto 101 Media   |   Ad
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Claim your FREE book now before it's too late!